Despite the promising results of the pre-clinical studies suggesting VEGF as a therapeutic target in pancreatic cancer, phase III trials of gemcitabine plus anti-angiogenic therapy with bevacizumab or axitinib (a VEGFR inhibitor) failed to reach their primary endpoint of OS [53,63,83,115]. Here, VEGFA is linked to pancreatic neoplasm.